Simplify Logo
argenx

argenx

Biotech immunology company developing therapeutic antibodies

Medical Safety Lead

Full-TimeUpdated on 9/19/2026
$292k - $401.5k/yr

+ Short-term incentive + Long-term incentive

Expert
MD
Remote in USA
Remote

About the job

Requirements
  • Provide strategic medical safety leadership and practical contributions in a cross-functional setting.
  • Knowledge of pharmacovigilance, including safety signal management and safety data review in clinical and post-marketing settings.
  • Knowledge of relevant global pharmacovigilance regulations and guidelines.
  • Excellent presentation skills with the ability to communicate complex issues clearly.
  • Strong scientific and analytic skills.
  • Ability to influence and collaborate with multidisciplinary teams.
  • Excellent problem-solving skills, with sound autonomy and applied judgment.
  • Relevant computer skills, including proficiency with Microsoft Office.
  • Fluency in written and spoken English.
  • MD degree or equivalent.
  • At least 10 years of relevant experience in the pharmaceutical or biotechnology industry, including at least 7 years in pharmacovigilance or drug safety.
  • Proven leadership, motivational, and interpersonal skills in a global and intercultural environment, including leading through influence without direct reporting lines and managing complex matrix teams.
  • Working knowledge of relevant pharmacovigilance regulatory requirements and guidance documents.
  • Demonstrated ability to perform medical assessments of safety data from multiple sources.
  • Experience with authoring complex documents and contributing to regulatory submissions.
  • Knowledge of adverse event reporting systems.
Responsibilities
  • Participate in cross-functional strategic planning and meetings.
  • Lead and contribute to safety signal management, benefit-risk assessment activities, and regular or ad hoc aggregate safety data reviews.
  • Contribute to the development of the overall safety governance structure and activities.
  • Provide safety strategies and accurate, timely, high-quality safety contributions for relevant sections of global regulatory submission documents, including integrated summaries of safety, summary clinical safety, and responses to regulatory authority inquiries.
  • Contribute to and ensure the completeness, accuracy, and quality of safety sections of clinical documents, including study protocols, investigator brochures, clinical study reports, and informed consent forms.
  • Lead the preparation of periodic safety reports, including periodic safety update reports and development safety update reports, and provide medical safety content while ensuring document consistency and quality.
  • Perform medical assessments of individual case safety reports when required.
  • Provide medical safety contributions at internal audits and regulatory inspections.
  • Support the development and updating of Global Patient Safety standard operating procedures and other controlled documents, including work instructions, forms, and templates.
  • Support product safety training and pharmacovigilance awareness activities across functions.
  • Lead the development, maintenance, and execution of Risk Management Plans and Risk Evaluation and Mitigation Strategies.
  • Contribute to updates of safety labeling sections and Core Data Sheets.
  • Provide strategic guidance and oversight on case processing activities.
  • Partner with Safety Operations on case quality issues, Medical Dictionary for Regulatory Activities coding, and case processing conventions.
  • Participate in cross-functional projects and initiatives.
  • Manage safety physicians as required.
  • Perform other tasks as required to assist in departmental activities.
Desired Qualifications
  • Global experience in pharmacovigilance or drug safety.
  • Experience in clinical practice or academic medicine.
  • Experience in epidemiology, biostatistics, clinical development, or medical affairs.

About the company

argenx develops antibody therapies to treat autoimmune diseases and cancer by translating scientific discoveries in immunology into therapeutic antibodies. Its work centers on R&D and then licensing and collaborations for commercialization, with cusatuzumab being developed with Janssen R&D to target hematological cancers such as leukemia. The company funds and accelerates discovery mainly through partnerships and licenses, bringing products to market via partner-based commercialization rather than building its own sales force. Its goal is to advance antibody-based treatments for serious autoimmune diseases and cancer by turning scientific insights into clinically useful therapies through industry and academic collaborations.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Ghent, Belgium

Founded

2008

Get referred to argenx

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 60% year over year to $1.54 billion.
  • August 17, 2026 ALKIVIA Phase 3 showed positive autoimmune myositis results, expanding the franchise.
  • BenchSci signed a two-year enterprise deal with argenx, signaling continued R&D investment and adoption.

What critics are saying

  • FDA issued two January 30, 2026 untitled letters for misleading VYVGART Hytrulo TV ads.
  • VYVGART still drives most revenue, so any launch stumble hits growth immediately.
  • FB102 needs celiac and alopecia data in 2026; failure weakens the $2.2 billion Forte bet.

What makes argenx unique

  • VYVGART became first approved gMG therapy across all serotypes on May 8, 2026.
  • argenx's SIMPLE Antibody platform and FcRn expertise create a durable discovery-to-commercialization moat.
  • August 27, 2026 Forte acquisition added FB102, deepening differentiated CD122 immunology coverage.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
The Montreal Gazette
Sep 2nd, 2026
BenchSci announces two-year enterprise agreement with argenx to advance ai-driven preclinical drug discovery.

BenchSci announces two-year enterprise agreement with argenx to advance ai-driven preclinical drug discovery. Scientist-led competitive selection deepens BenchSci's presence in European biopharma TORONTO - BenchSci, a leading provider of AI software for biopharma research and development, today announced a two-year enterprise agreement with argenx, a global immunology innovation company, to deploy EMET, BenchSci's agentic research environment for preclinical drug discovery, within the organization. Selected through a competitive evaluation...

Yahoo Finance
Sep 2nd, 2026
Argenx posts 18 consecutive quarters of sales growth, Q2 2026 revenue up 60% YoY

Argenx has achieved 18 consecutive quarters of revenue growth, with second-quarter 2026 sales rising 60% year-over-year and 17% sequentially. The biotech's Vyvgart and Vyvgart Hytrulo therapies continue gaining traction in treating severe autoimmune diseases. Earnings reached $472 million in Q2, nearly double the prior year, with expanding operating margins. The company holds approvals in generalised myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy. Argenx recently reported positive late-stage results for Vyvgart Hytrulo in autoimmune myositis, affecting around 100,000 Americans. Management sees this as a multibillion-dollar opportunity. The company expects Phase 3 results for empasiprubart in multifocal motor neuropathy during Q4 2026. CFO Karl Gubitz noted only 20% of gMG patients currently receive novel biologics, suggesting significant growth potential.

wallstreet:online AG
Aug 21st, 2026
Not Moderna: this biotech stock still has potential after an 11,000% rally!

Not Moderna: this biotech stock still has potential after an 11,000% rally! Since its IPO in 2014, the Argenx stock has risen by more than 11,150 percent. A study success is fueling new enthusiasm for Argenx. The background. Photo: Andrew Brookes - Westend61 Europe's largest listed pure-play biotech group currently knows only one direction: upwards. The Argenx stock has gained 21 percent since last Friday's closing price, marked a record high and is heading for its best week in more than three years. This puts it at the top of the winners in the Stoxx Europe 600, reports Bloomberg. The long-term record is even more spectacular: Since the Brussels listing in July 2014, the price has shot up by more than 11,150 percent. The market capitalization climbed to 55.4 billion euros - putting Argenx ahead of Moderna again. Trade your assessment of BioNTech SE ADR!

Yahoo Finance
Aug 18th, 2026
Argenx rises 11.5% after positive phase 3 trial for autoimmune myositis treatment

argenx reported positive Phase 3 results for its ALKIVIA trial evaluating VYVGART Hytrulo in adults with autoimmune myositis. The trial met its primary endpoint, with patients showing statistically significant improvements in Total Improvement Score over 52 weeks versus placebo. The study marks the first Phase 3 trial demonstrating benefit in immune-mediated necrotizing myopathy, a subtype with no approved targeted therapies. The safety profile remained consistent with prior studies. The company recently received US FDA priority review for VYVGART in seronegative generalized myasthenia gravis, with a decision expected on 10 May 2026. These label expansions could broaden VYVGART's reach across multiple autoimmune conditions. argenx's shares rose 11.5% following the announcement. The company's narrative projects $9.7 billion revenue and $3.5 billion earnings by 2029, requiring 22.3% yearly revenue growth.

Yahoo Finance
Aug 11th, 2026
argenx shares up 39% in a year, but analysts debate $775 fair value vs $867 close

argenx, a commercial-stage biopharma company specialising in autoimmune disease treatments, has attracted investor attention following recent share price movements. The stock closed at €767, up approximately 6% over the past week and 38.6% over the past year, bringing its market value to around €47.97 billion. The company generates revenue of €5.3 billion, primarily from its VYVGART franchise, with operations spanning the United States, Japan, China, and other markets. According to a widely followed valuation narrative, argenx appears 11.7% overvalued, with a fair value estimate of €686.43. The analysis credits the company's leadership in FcRn inhibitors and strong commercial growth, whilst noting typical biotech risks including single-asset dependence and pricing pressure. Revenue has doubled over two years, supporting the growth thesis.